Myles David C.

CH. DISCOV. & NON-CLIN DEV OFFOlema Pharmaceuticals, Inc. (OLMA) · full profile →Form 4 · filed Jan 14, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$3.1M
Net Open-Market Flow
-$3.1M
Transactions
9
7 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 14, 2026Sell(S)35K$28.99$1.0M543K
Jan 14, 2026Option exercise(M)50K$4.87$244K593K
Jan 14, 2026Sell(S)15K$28.60$429K578K
Jan 13, 2026Option exercise(M)50K$4.87$244K593K
Jan 13, 2026Sell(S)50K$27.60$1.4M543K
Jan 13, 2026Sell(S)200$28.49$6K543K
Jan 12, 2026Sell(S)10K$28.34$283K145K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 14, 2026Option exercise(M)50K$050K
Jan 13, 2026Option exercise(M)50K$0100K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001831216-26-000003) within minutes of acceptance. Every field above traces to the original document. Verify it directly: